Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Participation Type:

HIVR4P Home

Funding for this conference was made possible in part by 1R13AI136762-01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices or organizations imply endorsement by the U.S. Government.

The conference was supported by Gilead, which provided funding. Gilead has had no input into the content of the materials used at this meeting/conference.

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 13 of 13 from HIV Research for Prevention 2018
Plenary 02: What Happens First: Understanding Susceptibility, Transmission and Early Infection
Visualizing HIV Transmission and Prevention
Thomas Hope
Northwestern University, United States
First Responders: What Early Infection Teaches About Prevention and Functional Cure Strategies
Thumbi Ndung’u
University of KwaZulu-Natal, South Africa
Untangling Hormonal Impacts on the Vaginal Microbiome and HIV Acquisition Risk
Sharon Achilles
University of Pittsburgh, United States
from HIV Research for Prevention 2018 on 23 October 2018 08:30-10:00
Oral Abstract Session 01: Location, Location, Location: Mucosal Mediators of Risk
Role of Epithelial Cells and Fibroblasts From the Female Reproductive Tract in TFV and TAF Protection of CD4+ T Cells from HIV Infection
Charles Wira
Geisel School of Medicine at Dartmouth, United States
Optical Tissue Imaging and Spectroscopic Measurement of Spatiotemporal Tenofovir Distribution, Partitioning and Diffusivity in Vaginal and Rectal Mucosa
Oranat Chuchuen
Khon Kaen University, Faculty of Engineering, Thailand
Transplanted Human Vaginal Microbiomes Alter HIV-1 Infection and Tenofovir Efficacy in Colonized Vaginal Epithelial Multilayer Cultures
Richard Pyles
University of Texas Medical Branch, United States
Impact of Vaginal Bacteria Communities on Antiretroviral-based PrEP Drug Metabolism
Ryan Cheu
University of Washington, United States
Hormonal Contraception Induced Changes to the Female Genital Microbiota in South African Adolescents: A Randomized, Crossover Trial
Christina Balle
University of Cape Town, Institute of Infectious Disease and Molecular Medicine & Division of Immunology, South Africa
Reducing Inflammation as a Novel HIV Prevention Approach: Aspirin Reduces Inflammation and HIV Target Cells at the Female Genital Tract
Keith R Fowke
University of Manitoba, Canada
from HIV Research for Prevention 2018 on 23 October 2018 10:30-12:00
Oral Abstract Session 02: Immunity in Human Vaccine Trials
T-cell and Transcriptomic Responses to Prime-boost Strategies of 3 HIV Vaccines (MVA HIV-B; LIPO-5; GTU-MultiHIV B) - ANRS/INSERM VRI01 Trial
Jean-Daniel Lelièvre
Vaccine Research Institute/VRI, Hôpital Henri Mondor, France
Safety and Immunogenicity of a pDNA Clade B Env Prime, rVSV Clade C Env Boost HIV-1 Vaccination Regimen in a Phase 1 Clinical Trial
Gregory Wilson
Vanderbilt University Medical Center, United States
V1V2 IgG and Antibody Fc Effector Functions in a Subtype C ALVAC-HIV and Bivalent Subtype C gp120/MF59 HIV-1 Vaccine Trial in South Africa
Xiaoying Shen
Duke Human Vaccine Institute, United States
DNA-prime Induces Higher Magnitude Humoral Responses Than ALVAC-prime in HIV Vaccine Regimens With the Same Protein Boost
Zoe Moodie
Fred Hutchinson Cancer Research Center, United States
Vaccine-induced Gene Signature Correlates With Protection Against Acquisition in Three Independent Vaccine Efficacy Trials Including RV144
Rasmi Thomas
US Military HIV Research Program (MHRP), Walter Reed Army Institute of Research, United States
Primary Analysis of TRAVERSE: A Phase 1/2a Study to Assess Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost HIV Vaccine Regimens
Daniel J. Stieh
Janssen Vaccines & Prevention B.V., Netherlands
from HIV Research for Prevention 2018 on 23 October 2018 10:30-12:00
Oral Abstract Session 03: Structure and Maturation of bNAbs
Induction and Maturation of HIV-1 Fusion Peptide-directed Broadly Neutralizing Antibodies in Rhesus Macaques by Vaccination
Peter D. Kwong
Vaccine Research Center, United States
Identification of Near Pan-neutralizing Antibodies Against HIV-1 by Deconvolution of Plasma Humoral Responses
Mohammad Sajadi
Institute of Human Virology, School of Medicine, University of Maryland, United States
Structural Basis for Germline VRC01 Antibody Recognition of a Glycosylated HIV-1 Envelope CD4-binding Site
Marie Pancera
Fred Hutchinson Cancer Research Center, United States
Fast and Focused Maturation of VH1-2-restricted HIV-env CD4-binding Site Targeting bNAbs
Elise Landais
International AIDS Vaccine Initiative (IAVI), United States
Somatic hypermutation to counter a rare viral immunotype drove off-track antibodies in the CAP256-VRC26 V2-directed bNAb lineage
David Sacks
National Institute for Communicable Diseases, National Health Laboratory Service, South Africa
New SHIV Models of bNAb Elicitation and Env-Ab Coevolution
Hui Li
University of Pennsylvania, United States
from HIV Research for Prevention 2018 on 23 October 2018 10:30-12:00
Oral Abstract Session 04: Entry Into the PrEP Continuum
Tracking Global Oral PrEP Provision: The Who, What, Where of Oral PrEP
Laura Fitch
AVAC, United States
Sexual Health Goal Congruence and PrEP Adoption Among Gay and Bisexual Men in Primary Partnerships
Kristi Gamarel
University of Michigan School of Public Health, United States
Characterization of Early Adopters in a National Oral Pre-exposure Prophylaxis (PrEP) Scale-up Program in Kenya
Daniel Were
Jhpiego, Kenya
“So That I Don't Get Infected Even If I Have Sex With Someone Who Is Positive:” Factors Influencing PrEP Uptake Among Young Women in Kenya
Nicholas Thuo
Partners in Health Research and Development, Kenya
HIV-related Risks and Interest in Pre-exposure Prophylaxis (PrEP) Among Transgender Respondents of the Community-based Survey Flash! PrEP in Europe
Rosemary M. Delabre
Coalition PLUS, Community-based Research Laboratory, France
Substantial Gaps in the PrEP Continuum Among Transwomen Compared With MSM in San Francisco
Albert Liu
San Francisco Department of Public Health, United States
from HIV Research for Prevention 2018 on 23 October 2018 10:30-12:00
Oral Abstract Session 05: If I Choose, Will I Use? Products, People and Preferences
Acceptability of Long-acting Injectable Cabotegravir (CAB LA) in HIV-uninfected Individuals: HPTN 077
Elizabeth (Betsy) Tolley
FHI 360, United States
Partners, Peers and Rumours as Influencers of Use and Attitudes Towards the Dapivirine Vaginal Ring: Qualitative Data From The Ring Study (IPM 027)
Cecilia Milford
MatCH Research Unit (MRU), University of the Witwatersrand, South Africa
Testing Objective Markers of Placebo Vaginal Product Adherence in the Field
Andrea Ries Thurman
CONRAD Eastern Virginia Medical School, United States
Preference and Choice of Four Vaginal HIV Prevention Placebo Dosage Forms Among Young African Women: Results of the Quatro Randomized Crossover Trial
Elizabeth Montgomery
RTI International, United States
Attribute Preferences for Long-acting Pre-exposure Prophylaxis (PrEP): Results of a Discrete Choice Experiment With South African Youth
Alexandra Minnis
RTI International, United States
UChoose: An Adolescent Study of HIV Prevention Choice in Cape Town, South Africa
Katherine Gill
Desmond Tutu HIV Foundation, South Africa
from HIV Research for Prevention 2018 on 23 October 2018 13:00-14:30
Oral Abstract Session 06: Mucosal Models of Prevention
Combination of MUC5AC and MUC2 Enhances Antibody Neutralization Potency Against HIV-1 Infection
Arangassery Rosemary Bastian
Northwestern University, United States
Neutrophil Extracellular Traps Represent a Novel Mechanism for HIV Prevention in the Female Genital Tract
Marta Rodriguez-Garcia
Geisel School of Medicine at Dartmouth, United States
Select V2 Loop Antibodies Inhibit gp120 Binding to Integrin a4ß7
Sakaorat Lertjuthaporn
Faculty of Medicine Siriraj Hospital, Thailand
Investigating the Interactions Between HIV and a New Epithelial Target Cell in Human Genital Tissue
Jake Rhodes
Westmead Institute for Medical Research, Australia
Live Imaging of HIV-1 Transfer Across T-cell Virological Synapse to Epithelial Cells That Promotes Stromal Macrophage Infection
Morgane Bomsel
Institut Cochin CNRS UMR8104, France
Fca-receptor I Expression by Stratified Squamous Epithelia: Implications for IgA-associated Immune Function in the Human Lower Genital Tract
Kadryn Kadasia
Boston University School of Medicine, United States
from HIV Research for Prevention 2018 on 23 October 2018 13:00-14:30
Oral Abstract Session 07: Understanding Protection Against HIV From the T Cell Perspective
Increased Breadth of T-cell Responses After Mosaic HIV Vaccination in Humans (HVTN 106)
Nicole Frahm
Fred Hutchinson Cancer Research Center, United States
Gag and Env Conserved Element DNA Vaccines Elicit Cytotoxic Responses Targeting Subdominant Epitopes Able to Recognize Infected Cells in Macaques
Barbara K. Felber
National Cancer Institute at Frederick, United States
Utilizing Computational Machine Learning Tools to Understand Immunogenic Breadth of HIV in the Context of a CD8 T-cell Mediated HIV Response
Jonathan Hare
International AIDS Vaccine Initiative (IAVI), United Kingdom
Structure-based Network Analysis of HIV-1 Defines Protective CD8+ T Cell Epitopes Across Diverse HLA: Implications for Global Immunogen Design
Gaurav Gaiha
Ragon Institute of MGH, MIT & Harvard, United States
CD8+ T Cells Do Not Control SIV Replication During ART or Viral Relapse After ART Withdrawal
Afam Okoye
Oregon Health & Science University, United States
CD8 T Cells Responding to Adapted Epitopes Are Enriched in Chronic HIV Infection and Induce Dendritic Cell Maturation with Enhanced CD4 Infection
Kai Qin
University of Alabama at Birmingham, United States
from HIV Research for Prevention 2018 on 23 October 2018 13:00-14:30
Oral Abstract Session 08: bNAbs for Prevention
Combination of HIV-1 Antibodies 3BNC117 and 10-1074 Delays Viral Rebound During Treatment Interruption
Pilar Mendoza
Rockefeller University, United States
SHIV162P3 Transmission by Semen Leukocytes Is Efficiently Inhibited by a Combination of Broad Neutralizing Antibodies
Karunasinee Suphaphiphat
CEA, France
Broadly Neutralizing Antibodies Provide Potent Dose-dependent Protection to Rhesus Macaques Against Mucosal SHIV Challenge
Amarendra Pegu
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States
VRC01 Pharmacokinetics at Mucosal Sites in HIV-infected and Healthy Adults
Madhu SP Prabhakaran
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States
Safety and Pharmacokinetics of Multiple Doses of a Potent Anti-HIV Monoclonal Antibody, VRC01, in HIV-exposed Newborns
Coleen Cunningham
Duke, United States
Imaging the Distribution of I.V.-injected VRC01 and VRC01-LS in the In Vivo Rhesus Macaque Model
Ann M. Carias
Northwestern University, United States
from HIV Research for Prevention 2018 on 23 October 2018 13:00-14:30
Symposium 01: We Want bNAbs: Passively Infused and Induced by Vaccines
Engineered Tandem Bispecific Neutralising Antibody for HIV-1 Prevention and Immunotherapy
Zhiwei Chen
The University of Hong Kong AIDS Institute, China
Antibody Mediated Protection (AMP): Where Are We? Which Antibodies to Use and How Will We Know If It´s Working?
Lynn Morris
National Institute for Communicable Diseases of the NHLS, South Africa
Generation of Immunogens Based on HIV-1 Envelopes From Patients With Broadly Neutralizing Responses Within the First 6 Months of Infection
Eloisa Yuste
Instituto de Salud Carlos III, Spain
HIV-1 Vaccine Design for the Elicitation of V3-glycan Broadly Neutralizing Antibodies
Kevin Saunders
Duke Human Vaccine Institute, United States
Progress in Germline-targeting Vaccine Design for HIV
William Schief
The Scripps Research Institute and IAVI, United States
from HIV Research for Prevention 2018 on 23 October 2018 15:00-16:30
Symposium 02: Early Invaders: Establishment of HIV Infection
Selection of Transmitted Founder Viruses During Sexual HIV-1 Acquisition
Manish Sagar
Boston University, United States
Identification of a New HIV Transmitting Target Cell in Human Genital Tissue
Andrew Harman
The Westmead Institute, University of Sydney, Australia
Characteristics Leading to HIV Trapping in the Female Genital Tract and Systemic Primary Infection During Transmission
Eric Arts
University of Western Ontario, Canada
Mucosal Immunology in the Context of Acute HIV Infection and HIV Remission Studies
Alexandra Schuetz
MHRP Thailand, Thailand
from HIV Research for Prevention 2018 on 23 October 2018 15:00-16:30
Symposium 03: Beyond Placebo: Designing and Implementing Next Generation HIV Prevention Trials
Regulatory Perspectives for Streamlining HIV Prevention Trials
Jeffrey Murray
FDA, United States
Novel Trial Design in the Era of Successful HIV Prevention Interventions
Deborah Donnell
Fred Hutchinson Cancer Research Center, United States
The Landscape is Changing… [It's] Quite a Complicated Issue" : Perspectives on the Standard of Prevention in South African HIV Vaccine Trials
Zaynab Essack
Human Sciences Research Council, South Africa
Strengthen Community Expertise on the Important Aspects of Clinical Trial Design
Luciana Kamel
Fiocruz, Brazil
Community Engagement in the Design and Implementation of HIV Prevention Trials: Uganda Virus Research Institute-International AIDS Vaccine Initiative
Gertrude Nanyonjo
UVRI-IAVI HIV Vaccine Program, Uganda
Questions
Jeffrey Murray
FDA, United States
Deborah Donnell
Fred Hutchinson Cancer Research Center, United States
Zaynab Essack
Human Sciences Research Council, South Africa
Luciana Kamel
Fiocruz, Brazil
Gertrude Nanyonjo
UVRI-IAVI HIV Vaccine Program, Uganda
from HIV Research for Prevention 2018 on 23 October 2018 15:00-16:30
Symposium 04: ARVs for Prevention: Extrapolating from Data to Clinical Practice
Pharmacokinetics of PrEP Agents: Where Do Drugs Go? How Long Do They Last?
Marta Boffito
Chelsea and Westminster NHS Trust, United Kingdom
Lessons Learned from Pre-clinical Animal Models on Pharmacokinetics and Pharmacodynamics of ARVs for PrEP
Charles Dobard
Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, Laboratory Branch, United States
Understanding PrEP Effectiveness in Different Populations in the Context of Public Health Programs
Irene Mukui
National AIDS & STI Control Program, Kenya
The PrEP Paradigm for Prevention, Advocacy and Implementation in sub-Saharan Africa: Strong Starts, Short Cuts, and the Use (and Abuse?) of Data
Emily Bass
AVAC, United States
from HIV Research for Prevention 2018 on 23 October 2018 15:00-16:30
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 13 of 13 from HIV Research for Prevention 2018